Proteomics Intl Labs Ltd has released a press release.
December 2023 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Proteomics International Laboratories Ltd. on 6ix
In the deck
Story so far
Earlier from Proteomics International Laboratories
- PromarkerD licence with Omics Global extended to Chile
- US Medicare confirms reimbursement price for PromarkerD
- Proteomics receives $1.85 million in R&D tax incentive
- September 2023 Quarterly Activities Report and Appendix 4C
- Reinstatement to Quotation
Later from Proteomics International Laboratories
- Proteomics to raise $6.5m through Institutional Placement
- Study validates biomarkers for endometriosis blood test
- Study validates biomarkers for oesophageal cancer blood test
- European patent granted for OxiDx technology
- PromarkerD US commercialisation & Promarker pipeline update
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories